{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:45:46Z","timestamp":1787838346879,"version":"build-2784847793"},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2008,8,5]],"date-time":"2008-08-05T00:00:00Z","timestamp":1217894400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1136\/ard.2008.092767","type":"journal-article","created":{"date-parts":[[2008,8,7]],"date-time":"2008-08-07T00:34:04Z","timestamp":1218069244000},"page":"702-709","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":222,"title":["Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)"],"prefix":"10.1016","volume":"68","author":[{"given":"P J","family":"Mease","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Ory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J T","family":"Sharp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C T","family":"Ritchlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Van den Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Wellborne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Birbara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G T D","family":"Thomson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R J","family":"Perdok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Medich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R L","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D D","family":"Gladman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1136\/ard.2008.092767_bib1","doi-asserted-by":"crossref","first-page":"ii14","DOI":"10.1136\/ard.2004.032482","article-title":"Psoriatic arthritis: epidemiology, clinical features, course, and outcome.","volume":"64","author":"Gladman","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2008.092767_bib2","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1080\/00015550252948130","article-title":"Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study.","volume":"82","author":"Zachariae","year":"2002","journal-title":"Acta Derm Venereol"},{"key":"10.1136\/ard.2008.092767_bib3","first-page":"127","article-title":"Psoriatic arthritis (PSA): an analysis of 220 patients.","volume":"62","author":"Gladman","year":"1987","journal-title":"Q J Med"},{"key":"10.1136\/ard.2008.092767_bib4","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1517\/13543784.9.7.1511","article-title":"Psoriatic arthritis.","volume":"9","author":"Gladman","year":"2000","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1136\/ard.2008.092767_bib5","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1093\/rheumatology\/keg384","article-title":"A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience.","volume":"42","author":"Kane","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2008.092767_bib6","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/rheumatology\/30.4.245","article-title":"Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients.","volume":"30","author":"Torre Alonso","year":"1991","journal-title":"Br J Rheumatol"},{"key":"10.1136\/ard.2008.092767_bib7","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1067\/mjd.2002.119669","article-title":"The direct cost of care for psoriasis and psoriatic arthritis in the United States.","volume":"46","author":"Javitz","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1136\/ard.2008.092767_bib8","first-page":"721","article-title":"Employment across chronic inflammatory rheumatic diseases and comparison with the general population.","volume":"32","author":"Mau","year":"2005","journal-title":"J Rheumatol"},{"issue":"Suppl 2","key":"10.1136\/ard.2008.092767_bib9","doi-asserted-by":"crossref","first-page":"ii24","DOI":"10.1136\/ard.2004.030767","article-title":"Discussion: clinical features, epidemiology, classification criteria, and quality of life in psoriasis and psoriatic arthritis.","volume":"64","author":"Gladman","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2008.092767_bib10","first-page":"511","article-title":"Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis.","volume":"24","author":"Husted","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2008.092767_bib11","first-page":"241","article-title":"Long-term methotrexate therapy in psoriatic arthritis: clinical and radiological outcome.","volume":"22","author":"Abu-Shakra","year":"1995","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2008.092767_bib12","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1002\/art.20253","article-title":"Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial.","volume":"50","author":"Kaltwasser","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.092767_bib13","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/00124743-200106000-00005","article-title":"The long-term use of azathioprine in patients with psoriatic arthritis.","volume":"7","author":"Lee","year":"2001","journal-title":"J Clin Rheumatol"},{"key":"10.1136\/ard.2008.092767_bib14","first-page":"139","article-title":"Does injectable gold retard radiologic evidence of joint damage in psoriatic arthritis?","volume":"18","author":"Mader","year":"1995","journal-title":"Clin Invest Med"},{"key":"10.1136\/ard.2008.092767_bib15","first-page":"1957","article-title":"The use of sulfasalazine in psoriatic arthritis: a clinic experience.","volume":"25","author":"Rahman","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2008.092767_bib16","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.1780270403","article-title":"Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis.","volume":"27","author":"Willkens","year":"1984","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.092767_bib17","first-page":"809","article-title":"Longitudinal study of clinical and radiological progression in psoriatic arthritis.","volume":"17","author":"Gladman","year":"1990","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2008.092767_bib18","first-page":"675","article-title":"Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model.","volume":"22","author":"Gladman","year":"1995","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2008.092767_bib19","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1093\/rheumatology\/keg217","article-title":"Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study.","volume":"42","author":"McHugh","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2008.092767_bib20","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1136\/ard.62.1.68","article-title":"A polyarticular onset predicts erosive and deforming disease in psoriatic arthritis.","volume":"62","author":"Queiro-Silva","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2008.092767_bib21","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.20217","volume":"50","author":"Keystone","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.092767_bib22","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1136\/ard.2003.013052","article-title":"Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed.","volume":"63","author":"van de Putte","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2008.092767_bib23","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.","volume":"48","author":"Weinblatt","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.092767_bib24","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.092767_bib25","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/art.22379","article-title":"Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.","volume":"56","author":"Gladman","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.092767_bib26","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1136\/ard.2006.057901","article-title":"Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial.","volume":"66","author":"Gladman","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"10.1136\/ard.2008.092767_bib27","first-page":"391","article-title":"How much improvement in functional status is considered important by patients with active psoriatic arthritis: applying the outcome measures in rheumatoid arthritis clinical trials.","volume":"63","author":"Mease","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2008.092767_bib28","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/1529-0131(200007)43:7<1478::AID-ANR10>3.0.CO;2-M","article-title":"Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis.","volume":"43","author":"Kosinski","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.092767_bib29","first-page":"712","article-title":"Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept.","volume":"33","author":"Mease","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2008.092767_bib30","first-page":"869","article-title":"Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Controlled Trial (IMPACT).","volume":"35","author":"Antoni","year":"2008","journal-title":"J Rheumatol"},{"issue":"Suppl II","key":"10.1136\/ard.2008.092767_bib31","first-page":"524","article-title":"PASI 50 is a sensitive indicator of reduced radiographic progression in psoriatic arthritis patients treated with adalimumab (Humira): subanalysis of ADEPT.","volume":"67","author":"Choy","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2008.092767_bib32","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.0022-202X.2005.23621.x","article-title":"Translating the science of quality of life into practice: what do Dermatology Life Quality Index scores mean?","volume":"125","author":"Hongbo","year":"2005","journal-title":"J Invest Dermatol"},{"key":"10.1136\/ard.2008.092767_bib33","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1136\/ard.2005.043166","article-title":"Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis.","volume":"65","author":"Schiff","year":"2006","journal-title":"Ann Rheum Dis"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724422917?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724422917?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2008.092767","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T08:50:15Z","timestamp":1739523015000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724422917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["S0003496724422917"],"URL":"https:\/\/doi.org\/10.1136\/ard.2008.092767","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2008.092767","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 \u00a9 Mease et al 2009, Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}